How COVID-19 is changing the production of cell therapies

Implementation of contingency plans allows for continued progress in therapy development

Managing donor collections during the COVID-19 pandemic

Why a diverse apheresis center network is critical to business continuity

Quality Starting Material: The Driving Force Behind Life-Saving Cell Therapies

By Jamie Margolis, PhD, Senior Vice President of Donor Services, NMDP/Be The Match

Overcoming challenges to cellular starting material collection

Q&A with the Be The Match BioTherapies Collection Network Liaison team

The benefits of a Quality System Audit Program

Accelerate patient access to cell and gene therapies

Standardization in cell therapy industry is a race against time

Accellerate Summit highlights needs and challenges in standardization

The challenge of multiple audits and redundant training

A case study from UCLA Health

Developing and managing a strong collection center network

On-demand webinar available

Three things to know about efficient qualification of collection centers